Skip to main content
OpenTrials
Completed

NCT Number: NCT00234897

Efficacy of HUMIRA in Subjects With Active Rheumatoid Arthritis

The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Global Medical Information - Abbott

North Chicago, Illinois, 60064, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
  • Subject, based on assessment of investigator, meets the definition of active RA

Exclusion criteria

  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant

Treatment and study plan

Adalimumab

Drug

Primary outcomes

  1. Patient reported outcomes, clinical response indicators.

Secondary outcomes

  1. Subject reported assessments of disease activity, physician reported assessments of disease activity, safety parameters, clinical response indicators.

Sponsors and collaborators

Lead sponsor

Abbott

Industry

Registry information

Official study title

Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)

Acronym: HERO

Important dates

Study start
2004
First posted
Oct 10, 2005
Registry last updated
Aug 29, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.